Drug intelligence / Profile preview

Testisvac

Development stage: Preclinical
Lead developer: Innovita Research
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Testisvac is an investigational cell-based cancer vaccine and cell therapy developed by Innovita Research. It is designed to target cancer/testis antigens (CTAs), a class of tumor-associated antigens that are normally expressed in the human germline (such as the testis and placenta) but are frequently re-expressed in various types of cancer. Because CTAs are not typically found in healthy adult somatic tissues, they serve as ideal targets for immunotherapy to minimize off-target effects. Testisvac is currently in the preclinical stage of development for the treatment of cancers that express these specific antigens.

Brand names: Testisvac

Targets

T-cell receptor recognizing Cancer-Testis Antigen-derived peptide–MHC complex

Beyond the preview

Go deeper on Testisvac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Testisvac.

Explore the full profile